EFPIA - NEWSLETTER

Trouble reading this email? View it in your browser


		EFPIA Newsletter 7 March 2024

Make or break: The future of Regulatory Data Protection in Europe

A blog by Nathalie Moll

RDP is one part of Europe’s intellectual property ecosystem. Its purpose is to attract, stimulate and support investment and innovation in medicines development in Europe. The Commission’s proposal is to cut RDP by 2 years at a time when the European Council Conclusions asked to strengthen, rather than cut, the region’s incentives. If this happens, we will see not only a reduction in European competitiveness, but a significant reduction in patients’ access to medicines.

How to Unlock the Power of Drug Repurposing? EFPIA perspective
06 March 2024 - Sini Eskola - Tamara Di Carlantonio - Grímur Johannsson

We propose principles to guide policies and legislations that will ensure safety and efficacy of repurposed drugs. Read more

Events

DIA Europe 2024
12 March 2024 (Brussels)

... Read more

EU-X-CT Public Stakeholders' Forum
12 April 2024 (Brussels and online)

Making cross-border access to clinical trials a reality Read more

Rare Diseases Forum: Securing Europe’s competitiveness in R&D for people living with rare diseases...
16 April 2024 (Brussels)

Join to address how and why innovation in tackling rare diseases can support the EU’s competitiveness agenda. Read more

EMSP Annual Conference 2024
19 April 2024 (Brussels)

Apply to present your campaign posters by 28th February 2024. Read more

Imagine a Europe where patients get faster and more equitable access to medicines

Our aspiration is that all Europeans get access to new medicines on day one following authorisation. How do we make that a reality? Read more on our proposals to ensure faster, more equitable access for patients

What we are reading

Scientific progress: A look ahead
On 05 March 2024 (POLITICO)

An op-ed by Alberto Colzi, SVP and President International Therapeutics, AbbVie; Incoming... Read more

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
E-mail:Communications@efpia.eu